fluorodeoxyglucose f18 has been researched along with Impaired Glucose Tolerance in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, B; Cheng, J; He, F; Koyama, H; Liu, W; Lu, J; Wang, M; Wang, Q; Wang, W; Xi, Y; Xu, C; Yamamoto, T; Yan, Y; Yu, L; Yu, W; Zhang, C; Zhao, H | 1 |
| da Costa, A; Decaris, J; Foretz, M; Grueter, R; Lanz, B; Maechler, P; Metref, S; Minehira, K; Poitry-Yamate, C; Preitner, F; Schütz, F; Seyer, P; Staels, B; Tarussio, D; Thorens, B; Turner, S; Vallois, D | 1 |
| Abe, T; Fukumoto, Y; Honda, A; Ikeda, H; Imaizumi, T; Ishibashi, M; Kaida, H; Kodama, N; Mizoguchi, M; Narula, J; Nitta, Y; Tahara, A; Tahara, N; Yamagishi, S | 1 |
| Bartoli, A; Burchielli, S; Guzzardi, MA; Iozzo, P; Kemeny, A; Panetta, D; Salvadori, PA; Sanguinetti, E | 1 |
| Baik, SH; Choi, DS; Choi, KM; Kim, NH; Kim, S; Kim, SG; Kim, TN; Seo, JA; Yang, SJ; Yoo, HJ | 1 |
| Finn, AV; Tawakol, A | 1 |
| Harada, H; Hayabuchi, N; Ikeda, H; Imaizumi, T; Ishibashi, M; Kaida, H; Kodama, N; Mawatari, K; Mizoguchi, M; Nitta, Y; Oba, T; Tahara, A; Tahara, N; Yamagishi, S; Yasukawa, H | 1 |
| Marwick, TH; Narula, J | 1 |
2 trial(s) available for fluorodeoxyglucose f18 and Impaired Glucose Tolerance
| Article | Year |
|---|---|
Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus.
Topics: Administration, Oral; Aged; Body Fat Distribution; Diabetes Mellitus, Type 2; Female; Fluorodeoxyglucose F18; Glucose Intolerance; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Male; Middle Aged; Multimodal Imaging; Pioglitazone; Positron-Emission Tomography; Subcutaneous Fat; Sulfonylurea Compounds; Thiazolidinediones; Tomography, X-Ray Computed | 2013 |
Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta.
Topics: Aged; Anti-Inflammatory Agents; Aortic Diseases; Aortography; Biomarkers; Blood Glucose; C-Reactive Protein; Carotid Artery Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fluorodeoxyglucose F18; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Japan; Male; Middle Aged; Multimodal Imaging; Pioglitazone; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Regression Analysis; Sulfonylurea Compounds; Thiazolidinediones; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
6 other study(ies) available for fluorodeoxyglucose f18 and Impaired Glucose Tolerance
| Article | Year |
|---|---|
Hyperuricemia contributes to glucose intolerance of hepatic inflammatory macrophages and impairs the insulin signaling pathway
Topics: AMP-Activated Protein Kinases; Animals; Cytokines; Diabetes Mellitus, Type 2; Fluorodeoxyglucose F18; Glucose; Glucose Intolerance; Glucose Transporter Type 4; Hyperuricemia; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Kupffer Cells; Mice; Phosphatidylinositol 3-Kinases; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Urate Oxidase; Uric Acid | 2022 |
Hepatic glucose sensing is required to preserve β cell glucose competence.
Topics: Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Bile Acids and Salts; Blood Glucose; Cells, Cultured; Cholesterol; Down-Regulation; Energy Metabolism; Feces; Fluorodeoxyglucose F18; Gene Knockout Techniques; Glucose; Glucose Intolerance; Glucose Transporter Type 2; Homeostasis; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Lipid Metabolism; Liver; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Knockout; Nuclear Proteins; Radionuclide Imaging; Radiopharmaceuticals; Transcription Factors; Transcriptome | 2013 |
Elevated glycemia and brain glucose utilization predict BDNF lowering since early life.
Topics: Aging; Animals; Animals, Newborn; Blood Glucose; Brain; Brain Chemistry; Brain-Derived Neurotrophic Factor; Female; Fetus; Fluorodeoxyglucose F18; Genotype; Glucose; Glucose Intolerance; Humans; Hyperglycemia; Infant; Infant, Newborn; Leptin; Male; Obesity; Positron-Emission Tomography; Rats; Rats, Zucker | 2018 |
Vascular inflammation in patients with impaired glucose tolerance and type 2 diabetes: analysis with 18F-fluorodeoxyglucose positron emission tomography.
Topics: Adiponectin; Analysis of Variance; Biomarkers; C-Reactive Protein; Carotid Artery Diseases; Case-Control Studies; Chi-Square Distribution; Diabetes Mellitus, Type 2; Female; Fluorodeoxyglucose F18; Glucose Intolerance; Humans; Inflammation; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Risk Factors; Statistics, Nonparametric; Tunica Intima; Tunica Media | 2010 |
Imaging inflammatory changes in atherosclerosis multimodal imaging hitting stride.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Aortic Diseases; Aortography; Atherosclerosis; Carotid Artery Diseases; Contrast Media; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fluorodeoxyglucose F18; Glucose Intolerance; Humans; Hypoglycemic Agents; Inflammation; Magnetic Resonance Angiography; Male; Multimodal Imaging; Pioglitazone; Positron-Emission Tomography; Radiopharmaceuticals; Sulfonylurea Compounds; Thiazolidinediones; Tomography, X-Ray Computed | 2011 |
Imaging of pharmacologic intervention decoding therapeutic mechanism or defining effectiveness?
Topics: Anti-Inflammatory Agents; Aortic Diseases; Aortography; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fluorodeoxyglucose F18; Glucose Intolerance; Humans; Hypoglycemic Agents; Inflammation; Male; Multimodal Imaging; Pioglitazone; Positron-Emission Tomography; Radiopharmaceuticals; Sulfonylurea Compounds; Thiazolidinediones; Tomography, X-Ray Computed | 2011 |